Brokers Set Expectations for CHRS Q3 Earnings

Coherus Oncology, Inc. (NASDAQ:CHRS) – Stock analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Coherus Oncology in a research note issued on Thursday, October 29th. HC Wainwright analyst S. Ramakanth expects that the biotechnology company will earn ($0.22) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Coherus Oncology’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Coherus Oncology’s Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.91) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.17) EPS, Q3 2027 earnings at ($0.16) EPS, Q4 2027 earnings at ($0.13) EPS, FY2027 earnings at ($0.63) EPS, FY2028 earnings at ($0.48) EPS, FY2029 earnings at ($0.19) EPS and FY2030 earnings at $0.19 EPS.

Separately, Weiss Ratings upgraded shares of Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Coherus Oncology Stock Down 9.7%

CHRS opened at $0.75 on Monday. The firm has a market cap of $115.78 million, a price-to-earnings ratio of -0.73 and a beta of 0.98. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.70 and a current ratio of 1.77. The firm’s 50-day simple moving average is $1.18 and its 200-day simple moving average is $1.52. Coherus Oncology has a twelve month low of $0.75 and a twelve month high of $2.62.

Coherus Oncology (NASDAQ:CHRS) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.06. Coherus Oncology had a negative return on equity of 222.75% and a negative net margin of 259.41%. The company had revenue of $14.31 million during the quarter, compared to analysts’ expectations of $14.41 million.

Institutional Trading of Coherus Oncology

Large investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Coherus Oncology during the second quarter worth approximately $16,805,000. Sei Investments Co. increased its holdings in shares of Coherus Oncology by 492.2% in the first quarter. Sei Investments Co. now owns 453,763 shares of the biotechnology company’s stock valued at $767,000 after purchasing an additional 377,134 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Coherus Oncology in the second quarter valued at approximately $531,000. Renaissance Technologies LLC increased its holdings in shares of Coherus Oncology by 140.5% in the first quarter. Renaissance Technologies LLC now owns 331,700 shares of the biotechnology company’s stock valued at $561,000 after purchasing an additional 193,800 shares in the last quarter. Finally, Bank of America Corp DE raised its position in Coherus Oncology by 190.2% in the 1st quarter. Bank of America Corp DE now owns 324,133 shares of the biotechnology company’s stock worth $548,000 after purchasing an additional 212,430 shares during the last quarter. Institutional investors own 72.82% of the company’s stock.

About Coherus Oncology

Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.